

**PUBLISHED BY
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY**

**©The Medical Research Society and the Biochemical Society 1987
ISSN 0143-5221**

Printed in Great Britain by Whitstable Litho Ltd, Whitstable, Kent

Volume 72

AUTHOR INDEX

- Abdel-Rahman, A.-R.A. 113-122
Adami, S. 329-334
Adams, B. 415-422
Adams, L. 693-698
Addis, G.J. 135-138
Adnot, S. 467-473
Ala-Houhala, I. 289-296
Aldini, R. 11-17
Alexander, W.D. 737-741
Al-Saadi, A. 511-513
Al-Shamma, Y.M.H. 437-441
Alves, M.L.D. 239-244
Anderson, J.V. 305-312
Areas, J. 61-69
Armstrong, B.K. 343-350
Arnolda, L.F. 525-530
Aronson, J.K. 71-79
Askanazi, J. 489-501
Atarashi, K. 165-170
Atherton, J.C. 201-208
Attallah, A.A. 605-609
- Baldwin, J.C. 283-287
Balian, S. 61-69
Ball, S.G. 159-164
Ballantyne, D. 549-556
Barbara, L. 11-17
Baron, D.N. 171-179
Beacham, J. 305-312
Bean, B.L. 313-319, 321-327
Beastall, G.H. 737-741
Beetham, R. 245-249
Beilin, L.J. 343-350
Bell, J.D. 563-570
Bellavere, F. 55-60
Belledonne, M. 61-69
Bennett, T. 743-748
Berg, U. 611-620
Berthelot, A. 515-518
Besser, G.M. 181-185
Better, O.S. 139-141
Bing, R.F. 143-146, 599-604
Binkhorst, R.A. 475-482
Biollaz, J. 387-389
Bisgaard, H. 585-592
Blok, W.L. 147
Bloom, S.R. 217-223, 255-257, 305-312, 743-748
Bobinski, H. 201-208
- Bohlin, A.-B. 611-620
Boon, N.A. 71-79
Borsatti, A. 483-488
Bradlaugh, R. 143-146
Braga, V. 329-334
Branch, W.J. 87-94
Bronk, J.R. 705-716
Broughton Pipkin, F. 351-357
Brown, J.C.C. 563-570
Bruce, C. 209-216
Brunner, D.B. 387-389
Brunner, H.R. 387-389
Buckley, M.G. 531-539
Burke, C.M. 283-287
Burnett, D. 373-381
- Caló, L. 483-488
Campbell, A.K. 1-10
Cantaluppi, A. 329-334
Cantaro, S. 483-488
Cantin, M. 271-275
Cappelli, R. 329-334
Cappuccio, F.P. 531-539
Cardone, C. 55-60
Casati, S. 329-334
Catley, D.M. 149
Cattel, W. 245-249
Catto, G.R.D. 37-45
Chartier, L. 31-35
Chikenji, T. 489-501
Clark, A.G. 743-748
Clark, C.G. 463-466
Clark, M.L. 593-598
Clarke, E. 277-282
Cleland, J.G.F. 159-164
Cockcroft, A. 693-698
Coerwinkel, M.M. 475-482
Colyer, J. 593-598
Connell, J.M.C. 737-741
Corcoran, J.S. 225-232, 557-562
Cornell, J.E. 429-436
Coruzzi, P. 639-645
Cunningham, C. 37-45
- Dambrink, J.H.A. 335-341
Danforth, Jr., E. 489-501
Dargie, H.J. 159-164
Davies, D.L. 737-741
Dawnay, A. 245-249
- de Leeuw, P.W. 147
de Vasconcelos, P.R.L. 683-691
Dieguez, C. 621-627
Di Marzio, L. 443-447
Ding, J.L. 71-79
Distler, A. 131-134
Di Virgilio, F. 483-488
Djaldetti, M. 669-672
Domin, J. 255-257
Donckier, J. 305-312
Duggan, K.A. 195-200
- Ede, R.J. 365-371
Eisenhofer, G. 251-254
Elwyn, D.H. 489-501
Espiner, E.A. 19-24
Evans, D.F. 743-748
Exinger, A. 515-518
- Farthing, M.J.G. 593-598
Favaro, S. 483-488
Fedele, D. 55-60
Fellows, I.W. 259-261, 743-748
Ferri, M. 55-60
Ferry, N. 467-473
Fishman, P. 669-672
Forsling, M.L. 25-30
Fowler, M.B. 283-287
Freyschuss, U. 611-620
Frost, P.F. 217-223
Fuessl, H.S. 255-257
Fujishima, M. 571-576
Fukuchi, S. 699-704
- Gallo, Jr., L. 239-244
Genest, J. 271-275
Gibbons, R. 673-678
Gibson, J.N.A. 503-509
Gibson, S. 359-363
Giebisch, G. 139-141
Gil, K.M. 489-501
Goode, A. 511-513
Goodlad, R.A. 297-304
Gorchein, A. 103-112
Gove, C.D. 365-371
Grahame-Smith, D.G. 71-79
Grassi, G. 639-645
Graves, J. 415-422
Graziani, G. 329-334

- Green, R. 139-141, 201-208
 Green, S.T. 233-238
 Grimble, R.F. 383-385
 Groth, S. 585-592
 Guckian, V. 139-141
 Guz, A. 693-698
- Haigh, M. 359-363
 Hainsworth, R. 437-441
 Hall, J.E. 429-436
 Hall, P.E. 679-682
 Hall, R. 621-627
 Haller, H. 131-134
 Halliday, D. 503-509
 Halperin, M.L. 577-583
 Hamet, P. 271-275
 Hanoune, J. 467-473
 Harris, P.E. 621-627
 Hart, J. 669-672
 Hashimoto, S. 699-704
 Hickman, P.E. 725-735
 Higgins, B.E. 409-414
 Hill, S.E. 209-216
 Hirata, Y. 165-170
 Hiwatari, M. 525-530
 Hjelm, M. 187-193
 Hjemdahl, P. 47-54
 Hornsby, G.A. 503-509
 Hughes, R.D. 365-371, 563-570
 Huisman, R.M. 391-398
 Hunt, S.A. 283-287
- Iazigi, N. 239-244
 Inagami, T. 699-704
 Ishii, M. 165-170
 Ishimitsu, T. 165-170
- Jackson, C.A. 657-667
 Jackson, J. 277-282
 Jacobs, P. 415-422
 James, W.P.T. 81-86, 87-94, 95-102
 Jamieson, S.W. 283-287
 Jayaraj, A.P. 463-466
 Jeffery, P.K. 629-637
 Jendroska, K. 131-134
 Johansson, B.-L. 611-620
 Johnson, R.H. 251-254
 Johnston, C.I. 525-530
 Johnston, G.D. 749-756
 Jones, B.J.M. 409-414
 Joosten, E.M.G. 475-482
- Kangawa, K. 165-170
 Kastrup, J. 123-130
- Kay, J.D.S. 187-193
 Kendall, M.J. 679-682
 Kenna, J.G. 263-270
 Kerr, D.J. 737-741
 Kettlewell, M.G.W. 683-691
 Khaikina, L.I. 541-548
 Khan, F.A. 171-179
 Kinney, J.M. 489-501
 Kleeman, K. 657-667
 Knight, K.R. 673-678
 Kojo, S. 455-461
 Kondowe, G.B. 749-756
 Kramps, J.A. 373-381
 Kribben, A. 131-134
 Kumar, P.J. 593-598
 Kunes, J. 271-275
 Kunii, N. 699-704
- Lacombe, M.-L. 467-473
 Lambie, D.G. 251-254
 Lane, R. 693-698
 Larsson, K. 47-54
 Lassen, N.A. 123-130
 Leckie, B.J. 159-164
 Leeman, M. 717-724
 Lefvert, A.-K. 611-620
 Lejeune, P. 717-724
 Lenz, T. 131-134
 Levin, S.L. 541-548
 Lewin, M.R. 463-466
 Lewis, B.M. 621-627
 Lister, N. 705-716
 Littler, W.A. 423-428
 Lo Cascio, V. 329-334
 Lüdersdorf, M. 131-134
 Luthringer, C. 515-518
 Lynch, S. 705-716
 Lytras, N. 181-185
- Macdonald, G.J. 195-200
 Macdonald, I.A. 259-261, 743-748
 MacGregor, G.A. 25-30, 531-539
 Maciel, B.C. 239-244
 Maciel, L.M.Z. 239-244
 Macleod, A.F. 563-570
 Maguire, M. 277-282
 Mancia, G. 639-645
 Mansell, P.I. 259-261
 Margetts, B.M. 343-350
 Marin-Grez, M. 449-454
 Marin Neto, J.A. 239-244
 Markandu, N.D. 25-30, 531-539
 Marriott, C. 629-637
- Marshall, W. 365-371
 Martinsson, A. 47-54
 Matsuo, H. 165-170
 Matsuoka, H. 165-170
 Matter, M. 415-422
 McConway, M.G. 737-741
 McIntyre, G.D. 159-164
 Mélot, C. 717-724
 Mercey, D. 277-282
 Merrill, R.H. 113-122
 Michael, C.A. 725-735
 Milledge, J.S. 149
 Miyata, A. 165-170
 Miyoshi, M. 455-461
 Mizuno, K. 699-704
 Montani, J.-P. 429-436
 Morrill, L. 657-667
 Morris, A.J. 283-287
 Morrison, H.M. 151-158, 373-381
 Morrison, R. 351-357
 Morrison, W.L. 503-509
 Morselli-Labate, A.M. 11-17
 Motomura, K. 571-576
 Mueller, U.W. 725-735
 Murdoch, G. 503-509
 Musiari, L. 639-645
 Myburgh, K. 415-422
- Naeije, R. 717-724
 Nakata, R. 455-461
 Neo, G.-E. 359-363
 Neuberger, J. 263-270
 Ngu, J.L. 519-524
 Nicholls, M.G. 19-24
 Niimura, S. 699-704
 Noakes, T.D. 415-422
 Nørgaard, T. 123-130
 Northcote, R.J. 549-556
 Novarini, A. 639-645
 Nussberger, J. 387-389
- Oberholzer, V.G. 187-193
 Obika, L.F.O. 449-454
 O'Brien, P.M.S. 351-357
 Oei, T.L. 475-482
 Oesterle, S.N. 282-287
 Ogawa, K. 525-530
 Oh, V.M.S. 71-79
 Oh, Y. 571-576
 Ojima, M. 699-704
 Okuda, S. 571-576
 Olsen, M.E. 429-436
 O'Malley, B.P. 277-282
 Onoyama, K. 571-576
 Orr, S. 511-513
 Owens, C.W.I. 225-232

- Paccola, G.M.F. 239-244
 Pang, S.C. 271-275
 Parati, G. 639-645
 Parving, H.-H. 123-130
 Passmore, A.P. 749-756
 Pasternack, A. 289-296
 Payne, N.N. 305-312
 Penny, E.S. 181-185
 Periti, M. 443-447
 Philipp, T. 131-134
 Piccoli, A. 483-488
 Ploth, D.W. 657-667
 Plumb, J.A. 297-304
 Poston, L. 647-655
 Potter, J.M. 725-735
 Power, D.A. 37-45
 Preuss, H.G. 61-69
- Quaglia, G. 443-447
- Rademacher, R. 657-667
 Ravogli, A. 639-645
 Read, N.W. 209-216
 Rees, K.R. 463-466
 Rees, L.H. 181-185
 Reid, J.L. 135-138
 Rennie, M.J. 503-509
 Richards, A.M. 159-164
 Robertson, J.I.S. 159-164
 Robin, E.D. 283-287
 Roda, A. 11-17
 Roda, E. 11-17
 Rogers, D.F. 629-637
 Rosenthal, F.D. 277-282
 Russell, G.I. 599-604
- Sadler, P.J. 563-570
 Sagnella, G.A. 25-30, 531-539
 Salih, M.M. 423-428
 Salvaggio, A. 443-447
 Sanai, T. 571-576
- Sanchez-Castillo, C.P. 81-86,
 87-94, 95-102
 Scanlon, M.F. 621-627
 Schiffrin, E.L. 31-35
 Schreij, G. 147
 Scott, J.E. 359-363
 Seakins, J.W.T. 187-193
 Seidell, J. 81-86
 Shore, A.C. 25-30, 531-539
 Shumway, N.E. 283-287
 Silk, D.B.A. 217-223, 409-414
 Silverton, N.P. 437-441
 Simoni, P. 11-17
 Singh, V.K. 737-741
 Sinkeler, S.P.T. 475-482
 Slater, J.D.H. 305-312
 Slemmer, D. 61-69
 Smith, S.A. 423-428
 Smith, S.R. 679-682
 Solomon, L.R. 201-208
 Sönksen, P.H. 563-570
 Sonnenberg, H. 577-583
 Sopwith, A.M. 181-185
 Spiller, R.C. 217-223
 Sprague, D. 511-513
 Stewart, J.S. 217-223
 Stinson, E.B. 282-287
 Stittfall, T. 415-422
 Stockley, R.A. 373-381
 Stoward, P.J. 503-509
 Straw, J.A. 313-319, 321-327
 Sugden, A.L. 313-319, 321-
 327
 Sugden, M. 511-513
 Sugimoto, Tokuchiro 165-170
 Sugimoto, Tsuneaki 165-170
 Swainson, C.P. 19-24
 Swales, J.D. 143-146, 599-604
- Tani, M. 699-704
 Tartarotti, D. 329-334
 Taylor, E.A. 71-79
- Theodore, J. 283-287
 Thiede, H.M. 131-134
 Thurston, H. 143-146, 599-
 604
 Tonolo, G. 159-164
 Tovey, F.I. 463-466
 Triffit, J.T. 399-408
 Tsukamoto, I. 455-461
 Tsuruda, H. 571-576
 Turner, N.C. 629-637
- Vandongen, R. 343-350
 Vankessel, A. 283-287
 Veress, A. 577-583
- Waeber, B. 387-389
 Waldron, N.M. 593-598
 Walker, R.G. 19-24
 Wan, J.M. 383-385
 Warrender, S. 95-102
 Watari, H. 699-704
 Watt, P.W. 503-509
 Webber, R. 103-112
 Welch, I. McL. 209-216
 West, M.L. 577-583
 Westerhof, N. 391-398
 Wevers, R.A. 475-482
 White, J.S. 463-466
 Whitehead, T.P. 95-102
 Whitesmith, R. 135-138
 Whyte, K.F. 135-138
 Wieling, W. 335-341
 Williams, R. 365-371, 563-570
 Williamson, D.H. 683-691
 Woodcock, E.A. 525-530
 Wooles, W.R. 113-122
 Wright, N.A. 297-304
- Yabe, R. 699-704
 Yandle, T.G. 19-24
 Youmbissi, T.J. 519-524
 Yudkin, J.S. 225-232, 557-562

Volume 72

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption, intestinal
5-fluorouracil 705-716
glucose 409-414
water, crypt cell production 297-304
N-Acetyl- β -D-glucosaminidase, renal excretion,
Haemaccel 245-249
Acetylsalicylic acid
cyclo-oxygenase inhibition, pulmonary blood
pressure 717-724
Acidosis, acute 61-69
Addison's disease, high urine K^+ 577-583
Adenosine 3':5'-cyclic monophosphate,
isoprenaline, β -adrenoceptor function
47-54
Adenosine 5'-phosphate deaminase deficiency,
muscle purine metabolism, exercise 475-482
Adenosine triphosphatase, Na^+ , K^+ -dependent
brain, hepatic failure 365-371
erythrocytes, thyroid disease 171-179
leucocytes, thyroid disease 171-179
lymphocytes, rubidium influx 71-79
Adenylate cyclase, platelet, plasmin 467-473
Adrenal gland, renin-angiotensin system 694-704
Adrenergic activity, hypermagnesaemia 131-134
 α -Adrenoceptors, ethanol 251-254
 β -Adrenoceptor
blockers, lipoproteins 549-556
terbutaline-induced desensitization 47-54
Age
kidney remnant, function 571-576
orthostatic reflexes 335-341
Airway reactivity, leukotriene D_4 585-592
Alanine, ornithine carbamoyltransferase deficiency
187-193
Albumin
liver taurocholate uptake 11-17
pregnancy, hypertension 725-735
renal excretion, exercise 611-619
renal excretion, Haemaccel 245-249
Aldosterone
atrial natriuretic peptide 19-24, 25-30, 31-35,
159-164, 165-170, 305-312
chronic renal failure, saline infusion 19-24
high urine K^+ 577-583
metoclopramide, hyperprolactinaemia 277-282
sodium depletion, atrial natriuretic peptide 31-35
Aldosteronoma, immunoreactive renin 699-704
Alloantibodies, pregnancy 37-45
Allogeneic pregnancy, RTI antigen 37-45
Allograft enhancement, mechanisms 37-45
Amiloride
kallikrein excretion, frusemide 449-454
transtubular K^+ gradient 577-583
 δ -Aminolaevulinic acid, plasma, cerebrospinal
fluid, saliva and erythrocytes 103-112
Ammonia
 β -adrenoceptor antagonists, exercise 679-682
kidney, glutamine loading 61-69
plasma, alanine 187-193
Ammoniogenesis, renal, acid-base perturbations
61-69
Angiotensin I, metabolism, converting enzyme
blockade 387-389
Angiotensin II
aldosterone, atrial natriuretic peptide 31-35
chronic renal failure, saline infusion 19-24
glomerular filtration 429-436
prostaglandin E_1 , pregnancy 351-357
renin-angiotensin system 699-704
Angiotensin converting enzyme activity, hypoxia
149
Anti-leucoprotease, lung lavage fluid 373-381
Arterial haemodynamics, hypertension 391-398*
Arteriovenous anastomoses, fingertip, blood flow
225-232, 557-562
Atrial natriuretic peptide
aldosterone 19-24, 25-30, 31-35
chronic renal failure, saline infusion 19-24
exercise 159-164
mineralocorticoid escape 531-539
physiological concentration 305-312
plasma renin activity 19-24, 25-30
posture 201-208
renin-aldosterone system 165-170
sodium chloride, dietary 201-208
sodium intake 25-30, 31-35
vasopressin release 525-530
Atropine, salivary electrolytes 541-548
Autonomic nervous system
blockade, heart rate 55-60
tachycardia, hyperthyroidism 239-244
thyroxine release 233-238

- Autonomic neuropathy, fingertip anastomotic
blood flow 557-562
- Baroreceptors, arterial, cardiopulmonary receptors
639-645
- Baroreflex sensitivity, ethanol 113-122
- Bartter's syndrome, neutrophil calcium 483-488
- Bile acids, albumin, liver uptake 11-17
- Bile salts
coeliac disease 217-223
proximal tubular reabsorption 139-141
- Blood flow
arterial haemodynamics 391-398*
fingertip 225-232, 557-562
kidney, angiotensin II, prostaglandins 429-436
kidney, verapamil 657-667
skin, diabetic autonomic neuropathy 557-562
skin, type 1 diabetic patients 123-130
- Blood pressure
arterial baroreceptors, cardiopulmonary receptors
639-645
arterial haemodynamics 391-398*
atrial natriuretic peptide 305-312, 525-530
caffeine, coffee 443-447, 749-756
dietary fibre 343-350
electrolytes 313-319, 321-327
ethanol 251-254
posture, age 335-341
pulmonary, hypoxia 717-724
water balance 321-327
- Blood vessels
aortic smooth muscle, sodium pump 143-146
cutaneous, distensibility 123-130
- Bone proteins 399-408*
- Breathlessness, arterial oxygen saturation 693-698
- Bromine, experimental hypertension 515-518
- 2-Bromoethylamine hydrobromide, experimental
papillary necrosis, haemodynamics 599-604
- Bronchi, aerosol challenge 585-592
- Bronchitis, chronic, cigarette smoke 629-637
- Bronchoalveolar lavage, anti-elastase activity, cell
profile 373-381
- Caffeine
blood pressure 443-447, 749-756
diuresis 749-759
- Calcium
channel blocking, hypertension 657-667
intracellular 1-10*, 131-134
intracellular, essential hypertension 647-655*
neutrophils, Bartter's syndrome 483-488
thymidine kinase 455-461
verapamil 657-667
- Captopril, arterial natriuretic peptide, renin-
aldosterone system 165-170
- Cardiac output
estimation, single breath method 437-441
experimental papillary necrosis 599-604
Valsalva's manoeuvre 423-428
- Cardiopulmonary receptors, arterial baroreceptors
639-645
- Cardiovascular test 55-60
- Catecholamines
atrial natriuretic peptide, exercise 159-164
brain, hypothyroidism 621-627
ethanol, blood pressure 251-254
- Cell division, intestinal, water absorption 297-304
- Cell injury, intracellular calcium 1-10*
- Cerebral oedema, Na⁺, K⁺-ATPase 365-371
- Cerebrospinal fluid
 δ -aminolaevulinic acid 103-112
high resolution proton n.m.r. 563-570
- Cigarette smoke
'chronic bronchitis' 629-637
emphysema 151-158*
- Circadian rhythm, thyrotrophin 737-741
- Clearance, renal
dextran 289-296
protein 289-296
- Clinical trial, randomized controlled 343-350
- Coeliac disease
gliadin binding, enterocytes 593-598
postprandial bile acids 217-223
- Coffee, blood pressure 443-447, 749-756
- Collagen
cross-link formation 673-678
fibril growth, muscle paralysis 359-363
skin, vinyl chloride 673-678
- Collecting ducts, kidney, K⁺ excretion 577-583
- Compensatory renal growth 571-576
- Converting enzyme inhibitors
angiotensin I metabolism 387-389
renal function, hypertension 657-667
- Copper, experimental hypertension 515-518
- Corticosteroid binding globulin,
pregnancy, hypertension 725-735
- Cortisol, pregnancy, hypertension 725-735
- Cough, heart rate 55-60
- Creatinine excretion, glucose intake, malnourish-
ment 489-501
- Cyclic AMP *see* Adenosine 3':5'-cyclic mono-
phosphate
- Cytoplasm, free calcium 1-10*
- Deoxyribonucleic acid
heart ventricles 271-275
kidney 271-275
liver 271-275
synthesis, thyroparathyroidectomy 455-461
- Dextran, renal clearance 289-296

- Diabetes mellitus**
 cerebrospinal fluid, proton n.m.r. 563-570
 cutaneous blood flow 557-562
 dextran clearance 289-296
 dietary management 209-216
 microangiopathy 123-130
 neuropathy 55-60
 protein clearance 289-296
 type 1, renal function, exercise 611-619
- Diet**
 fibre, blood pressure 343-350
 high K⁺/low Na⁺, blood pressure 313-319
 rice, gastrointestinal ulcers 463-466
 1,25-Dihydroxyvitamin D, extrarenal synthesis, glucocorticoids 329-334
- Diuresis, kallikrein excretion, frusemide 449-454**
- Dopamine**
 antagonist, aldosterone responsiveness 277-282
 brain, hypothalamic 621-627
 circadian rhythm, thyrotrophin 737-741
- Duodenum, lipid, glucose and insulin responses 209-216**
- Elastin, emphysema 151-158**
- Electrical field stimulation, autonomic nerves and thyroxine release 233-238**
- Electrolytes**
 excretion, exercise 611-619
 potassium/sodium, hypertension 313-319, 321-327
 saliva, neural control 541-548
 urine, adrenalectomy 577-583
- Element X-ray microanalysis, finger nail iron 669-672**
- Embryo tendon, collagen fibril growth 359-363**
- Emphysema, proteinase-antiproteinase theory 151-158***
- Enalapril, angiotensin I metabolism 387-389**
- Encephalopathy, brain Na⁺, K⁺-ATPase 365-371**
- Enterocytes, gliadin binding 593-598**
- Erythrocytes**
 δ -aminolaevulinic acid 103-112
 ion flux, thyroid disease 171-179
- Escherichia coli* endotoxin, dietary linoleate 383-385**
- Ethanol**
 baroreceptor reflex 113-122
 blood pressure reactivity 251-254
- Exercise**
 ammonia, β -adrenoceptor antagonists 679-682
 atrial natriuretic peptide, sodium 159-164
 breathlessness, arterial oxygen saturation 693-698
 cardiac output 437-441
 ischaemic isometric, purines 475-482
 maximum, iron/folate therapy 415-422
 renal function 611-619
- Extracellular fluid volume, chronic renal failure 19-24**
- Fats, linoleate content 383-385**
- Fibrosis, skin, 'vinyl chloride disease' 673-678**
- Finger**
 blood flow 225-232, 557-562
 nails, iron content 669-672
- 5-Fluorouracil, intestinal absorption 705-716**
- FPL 57231, leukotriene receptor blockade, pulmonary blood pressure 717-724**
- Focal glomerular sclerosis, uninephrectomy 571-576**
- Folate deficiency, exercise performance 415-422**
- Food intake, crypt cell production, intestinal water absorption 297-304**
- Fracture, tibia *see* Leg immobilization**
- Frusemide**
 kallikrein excretion, amiloride 449-454
- Galactosamine, hepatic failure, brain Na⁺, K⁺-ATPase 365-371**
- Gastric emptying, duodenal and ileal lipid 209-216**
- Gastrointestinal tract**
 crypt cell production, water absorption 297-304
 motility, hypoglycaemia 743-748
- Gliadin, binding, enterocytes 593-598**
- Glomerular diseases, tropics 519-524***
- Glomerular filtration rate**
 angiotensin II 429-436
 atrial natriuretic peptide 305-312
 converting enzyme inhibitor 657-667
 exercise 611-619
 verapamil 657-667
- Glomerulonephritis**
 dextran clearance 289-296
 protein clearance 289-296
 tropics 519-524*
- Glucocorticoids, extrarenal 1,25-dihydroxy-vitamin D 329-334**
- Gluconeogenesis, liver, sepsis 683-691**
- Glucose**
 absorption, intestinal 409-414
 duodenal and ileal lipid 209-216
- Glutamine, renal ammoniogenesis 61-69**
- γ -Glutamyltransferase, lymphocyte, ouabain binding 71-79**
- Glycaemia, duodenal and ileal lipid 209-216**
- Growth hormone releasing factor, source 181-185**
- Haemaccel, protein excretion 245-249**
- Haematin, plasma δ -aminolaevulinic acid 103-112**

- Haemodynamics**
arterial, hypertension 391–398*
experimental papillary necrosis 599–604
kidney, exercise 611–619
- Halothane hepatitis** 263–270*
- Head-out immersion, carotid baroreceptor stimulation** 639–645
- Heart**
baroreceptor reflex, ethanol 113–122
cough 55–60
dysrhythmias, magnesium 135–138
hyperplasia, hypertension 271–275
intrinsic rate 239–244
orthostatic reflexes, age 335–341
- Heart rate**
 β -adrenoceptor antagonists 679–682
arterial baroreceptors, cardiopulmonary receptors 639–645
hyperthyroidism 239–244
intrinsic 239–244
Valsalva's manoeuvre 423–428
- Hepatocytes, isolated, thyroid hormones** 511–513
- Hepatotoxins, halothane** 263–270*
- Histamine, leukotriene D₄, inhalation** 585–592
- Hyperammonaemia, alanine** 187–193
- Hyperkalaemia, adrenalectomy** 577–583
- Hypermagnesaemia, platelet calcium** 131–134
- Hyperoxia, pulmonary blood pressure** 717–724
- Hyperplasia, cardiac** 271–275
- Hyperprolactinaemia, aldosterone responsiveness to metoclopramide** 277–282
- Hypertension**
arterial haemodynamics 391–398*
caffeine, coffee 443–447, 749–756
converting enzyme inhibitor 657–667
diet, high K⁺/low Na⁺ 313–319
essential, pregnancy, cortisol 725–735
sodium pump inhibitors 647–655*
verapamil 657–667
- Hypertension, experimental**
heart hyperplasia 271–275
kidney hyperplasia 271–275
renal papillary necrosis 599–604
trace elements 515–518
- Hyperthyroidism**
autonomic nervous system, tachycardia 239–244
erythrocytes, ion flux 171–179
leucocytes, ion flux 171–179
- Hypoglycaemia, gastrointestinal motility** 743–748
- Hypomagnesaemia, adrenaline** 135–138
- Hypophysectomy, crypt cell production, intestinal water absorption** 297–304
- Hypothalamus**
catecholamines, hypothyroidism 621–627
growth hormone releasing factor 181–185
- Hypothyroidism**
brain catecholamines 621–627
erythrocytes, ion flux 171–179
leucocytes, ion flux 171–179
- Hypoxaemia, breathlessness, chronic obstructive airways disease** 693–698
- Hypoxia, pulmonary blood pressure** 283–287, 717–724
- Ileum, lipid, glucose and insulin responses** 209–216
- Immunoreactive atrial natriuretic peptide**
aldosterone 19–24, 25–30
chronic renal failure, saline infusion 19–24
plasma renin activity 19–24, 25–30
sodium intake 25–30
- Impedance cardiography, cardiac output, Valsalva's manoeuvre** 423–428
- Input resistance, thyroid follicular cells** 233–238
- Insulin**
duodenal/ileal lipid 209–216
hypoglycaemia, gastrointestinal motility 743–748
- Insulinaemia, duodenal and ileal lipid** 209–216
- Interleukin 1, dietary lineoleate** 383–385
- Intestine, small**
absorption, 5-fluorouracil 705–716
absorption, glucose 409–414
crypt cell production, water absorption 297–304
lipid, glucose and insulin responses 209–216
motility, hypoglycaemia 743–748
- Intracellular calcium**
free 1–10*
free, acute hypermagnesaemia 131–134
- Iron**
deficiency 415–422, 669–672
finger nail 669–672
- Ischaemia, muscle purine metabolism** 475–482
- Isoprenaline, lymphocyte cyclic AMP** 47–54
- Jejunum**
absorption, 5-fluorouracil 705–716
absorption, glucose 409–414
motility, hypoglycaemia 743–748
- Kallikrein-kinin system, amiloride** 449–454
- Ketogenesis, liver, sepsis** 683–691
- Kidney**
ammoniogenesis, acid-base balance 61–69
caffeine, coffee 443–447, 749–756
chronic renal failure, atrial natriuretic peptide 19–24
exercise, noradrenaline 611–619
high urine K⁺, adrenalectomy 577–583
hyperplasia, hypertension 271–275
medullary damage, haemodynamics 599–604

- Kidney (*continued*)
 renal failure, 1,25-dihydroxyvitamin D synthesis 329-334
 sodium taurocholate, proximal tubular re-absorption 139-141
 tubular proteinuria, Haemaccel 245-249
- Lactate
 exercise, iron and folate therapy 415-422
 'turnpoint' 415-422
- Lactation, crypt cell production, intestinal water absorption 297-304
- Lectin, gliadin binding, enterocytes 593-598
- Leg immobilization, muscle protein turnover 503-509
- Leukotrienes
 D₄, bronchi 585-592
 pulmonary blood pressure, hypoxia 717-724
- Lipid
 duodenum, glucose and insulin responses 209-216
 ileum, glucose and insulin responses 209-216
- Lipogenesis
 glucose intake, malnourishment 489-501
 liver, sepsis 683-691
- Lipoproteins, β -adrenoceptor blockers 549-556
- Lisinopril, angiotensin I metabolism 387-389
- Lithium
 dietary salt sources 81-86, 87-94, 95-102
 sodium chloride, dietary 201-208
- Liver
 deoxyribonucleic acid 271-275, 455-461
 failure, brain Na⁺, K⁺-ATPase 365-371
 failure, cerebrospinal fluid proton n.m.r. 563-570
 regeneration, DNA synthesis 455-461
 sepsis, metabolism 683-691
 taurocholate uptake, albumin 11-17
 thymidine kinase 455-461
 thymidylate synthetase 455-461
 toxins, halothane 263-270*
- Lung
 emphysema 151-158*
 lavage fluid, anti-elastase activity 373-381
 leukotriene D₄ 585-592
 transplant, hypoxic vasoconstriction 283-387
- Lymphocytes
 β -adrenoceptor function 47-54
 ouabain binding, rubidium influx 71-79
- Magnesium
 adrenaline 135-138
 platelet calcium 131-134
- Maltotriose, glucose absorption, intestinal 409-414
- Marathon runners, iron and folate therapy 415-422
- Maximum exercise performance, iron and folate therapy 415-242
- Membrane potential
 thyroid follicular cells 233-238
- Meningitis, cerebrospinal fluid proton n.m.r. 563-570
- Metoclopramide, aldosterone responsiveness, hyperprolactinaemia 277-282
- Metoprolol
 exercise, ammonia 679-682
 heart rate 679-682
- Microcirculation, skin, type 1 diabetic patients 123-130
- β_2 -Microglobulin, renal excretion, Haemaccel 245-249
- Microspheres, haemodynamics, experimental papillary necrosis 599-604
- Mineralocorticoid escape, atrial natriuretic peptide 531-539
- Motilin, gastrointestinal motility 743-748
- Mouth-caecum transit time, postprandial bile acids in coeliac patients 217-223
- Muscle, skeletal
 paralysis, collagen fibril growth 359-363
 purine metabolism, AMP deaminase deficiency 475-482
 respiratory, cardioacceleration 55-60
- Muscle, smooth
 aortic, sodium pump 143-146
 vascular, sodium metabolism 647-655*
- Nadolol
 exercise, ammonia 679-682
 heart rate 679-682
- Nails, finger, iron content 669-672
- Natriuresis
 atrial natriuretic peptide 305-312
 frusemide, kallikrein excretion 449-454
 vasoactive intestinal peptide 195-200
- Neck chamber, carotid baroreceptors, cardiopulmonary receptors 639-645
- Neonate, cardiac and renal hyperplasia 271-275
- Neutrophil, cytosolic calcium, Bartter's syndrome 483-488
- Neutrophil elastase
 emphysema 151-158*
 inhibitor, lung lavage fluid 373-381
- Nitrogen balance, glucose intake, malnourishment 489-501
- Noradrenaline
 brain, hypothyroidism 621-627
 caffeine 749-756
 chronic renal failure, saline infusion 19-24
 renal function, exercise 611-619
- Obstructive airways disease, arterial oxygen saturation 693-698

- Oligosaccharides, glucose absorption, intestinal 409–414
- Oral administration, somatostatin analogue SMS201–995, 255–257
- Ornithine carbamoyltransferase deficiency, urea synthesis 187–193
- Orotate, ornithine carbamoyltransferase deficiency 187–193
- Oxygen saturation, oxygen breathlessness 693–698
- Pancreatic elastase inhibitor, lung lavage fluid 373–381
- Paradoxical salivation 541–548
- Parasitic diseases, glomerulonephritis, tropics 519–524*
- Paralysis, tendon collagen fibril growth 359–363
- Parotid gland, electrolyte absorption 541–548
- Peptic ulcer *see* Ulcers, gastrointestinal
- pH, optimum, adrenocortical tumour renin 699–704
- Pharmacokinetics, somatostatin analogue SMS201–995 255–257
- Pindolol**
 exercise, ammonia 679–682
 heart rate 679–682
 lipoproteins 549–556
- Plasma renin activity
 atrial natriuretic peptide 525–530
 high K⁺/low Na⁺ diet 313–319
 sodium depletion 605–609
- Plasmin, platelet adenylate cyclase 467–473
- Platelets, adenylate cyclase, plasmin 467–473
- Porphyria, δ -aminolaevulinic acid 103–112
- Posture
 atrial natriuretic peptide 201–208
 heart rate, age 335–341
- Potassium
 caffeine 749–756
 erythrocytes, thyroid disease 171–179
 high K⁺ diet, hypertension 313–319, 321–327
 leucocytes, thyroid disease 171–179
 renal excretion, adrenalectomy 577–583
- Pregnancy
 angiotensin II, exogenous 351–357
 hypertension, corticosteroid binding protein 725–735
 intermittent porphyria, δ -aminolaevulinic acid 103–112
 prostaglandin E₁, exogenous angiotensin II 351–357
 semi-allogeneic, RT1 antigen 37–45
- Pressor responsiveness, ethanol 113–122
- Prolactin, hyperprolactinaemia, metoclopramide 277–282
- Propranolol
 exercise, ammonia 679–682
 heart rate 679–682
 lipoproteins 549–556
- Prostaglandin E₁, exogenous angiotensin II, pregnancy 351–357
- Prostaglandin E₂, sodium intake 605–609
- Prostaglandins
 glomerular filtration rate 429–436
 pulmonary blood pressure, hypoxia 717–724
- Proteins
 bone 399–408*
 muscle turnover, immobilization 503–509
 non-collagenous, bone 399–408*
 renal clearance 289–296
 urinary excretion, Haemaccel 245–249
- Proteinase–antiproteinase theory, emphysema 151–158*
- α_1 -Proteinase inhibitor
 deficiency, lung lavage fluid 373–381
 emphysema 151–158*
- Proteinuria
 diabetic nephropathy 289–296
 glomerular diseases, tropical 519–524*
 glomerulonephritis 289–296
- Proteoglycans, bone 399–408*
- Proton nuclear magnetic resonance, cerebrospinal fluid 563–570
- Pulmonary circulation, vasoconstriction, hypoxia 283–287
- Purines, muscle metabolism, AMP deaminase deficiency 475–482
- Pyrimidines, intestinal absorption 705–716
- Quadriceps muscle, immobilization, protein turnover 503–509
- Radiotelemetry, gastrointestinal motility 743–748
- Ramp method, baroreceptor reflex, heart rate 113–122
- Renin
 adrenocortical tumour 699–704
 aldosteronism 699–704
 angiotensin I, converting enzyme blockade 387–389
 angiotensin II, pregnancy 351–357
 atrial natriuretic peptide 159–164, 165–170
 chronic renal failure, saline infusion 19–24
- Renin–angiotensin system
 atrial natriuretic peptide 305–312
 caffeine 749–756
 converting enzyme blockade 387–389
 sodium intake, renal prostaglandin 605–609
- Renin–angiotensin–aldosterone system 159–164
- Retinol-binding protein, renal excretion, Haemaccel 245–249

- Reverse tri-iodothyronine, hepatocyte metabolism 511–513
- Rice, dietary, gastrointestinal ulcers 463–466
- R–R interval, cough response 55–60
- RT1A antigens, semi-allogeneic pregnancy 37–45
- Rubidium
 experimental hypertension 515–518
 influx (^{86}Rb), lymphocytes 71–79
- Salbutamol, plasma magnesium 135–138
- Saliva, δ -aminolaevulinic acid 103–112
- Salivary gland, electrolyte absorption 541–548
- Salt *see* Sodium chloride
- Scaling, subject assessment 693–698
- Selenium, experimental hypertension 515–518
- Sepsis, hepatic metabolism 683–691
- Sialoproteins, bone 399–408*
- Single breath method, cardiac output, exercise 437–441
- Skin blood flow, diabetic autonomic neuropathy 557–562
- Skeletal muscle *see* Muscle, skeletal
- Smooth muscle *see* Muscle, smooth
- Sodium
 atrial natriuretic peptide 25–30, 31–35, 159–164
 balance 87–94
 dietary sources 81–86, 87–94, 95–102
 erythrocytes, thyroid disease 171–179
 excretion, atrial natriuretic peptide 305–312
 intake, aortic smooth muscle 143–146
 kallikrein excretion, frusemide 449–454
 leucocytes, thyroid disease 171–179
 low Na^+ diet, hypertension 313–319, 321–327
 vasoactive intestinal peptide 195–200
- Sodium chloride
 atrial natriuretic peptide 201–208
 dietary, lithium marker 81–86, 87–94, 95–102
- Sodium efflux rate constant, aortic smooth muscle 143–146
- Sodium pump inhibitors, essential hypertension 647–655*, 657–667
- Sodium taurocholate
 proximal tubular reabsorption 139–141
- Somatostatin analogue, SMS201-995, oral administration 255–257
- Starvation, crypt cell production, intestinal water absorption 297–304
- Steady state method, baroreceptor reflex, heart rate 113–122
- Stroke volume, Valsalva's manoeuvre 423–428
- Sucrose, glucose absorption, intestinal 409–414
- Tachycardia, autonomic nervous system in hyperthyroidism 239–244
- Taurocholate, liver uptake, albumin 11–17
- Tendon, collagen fibril growth, paralysis 359–363
- Terbutaline, β -adrenoceptor desensitization 47–54
- Thermal clearance probe, fingertip blood flow 225–232
- Thermogenesis
 diet-induced 259–261
 glucose intake, malnourishment 489–501
- Thromboxane A_2 , renal, sodium intake 605–609
- [^3H]Thymidine, lymphocyte uptake 71–79
- Thymidylate synthetase, liver 455–461
- Thymine, intestinal absorption 705–716
- Thyroid gland innervation, hormone release 233–238
- Thyroid hormone, liver regeneration 455–461
see also Thyroxine, Reverse tri-iodothyronine, Tri-iodothyronine
- Thyroparathyroidectomy, DNA synthesis 455–461
- Thyrotrophin
 circadian rhythm, dopamine 737–741
 metoclopramide, hyperprolactinaemia 277–282
- Thyroxine secretion, autonomic nerves 233–238
- Tobacco *see* Cigarette smoke
- Trace elements, experimental hypertension 515–518
- Transcortin, pregnancy, hypertension 725–735
- Transplant, heart–lung, hypoxic pulmonary vasoconstriction 283–287
- Tri-iodothyronine, hepatocyte metabolism 511–513
- Transport
 intestinal, pyrimidines 705–716
 sodium, essential hypertension 647–655*
- Tropical countries, glomerular diseases 519–524*
- Tyrosine, brain, hypothyroidism 621–627
- Ulcers, gastrointestinal, rice 463–466
- Uracil, intestinal absorption 705–716
- Uraemia, δ -aminolaevulinic acid 103–112
- Urea excretion, glucose intake, malnourishment 489–501
- Urea synthesis, ornithine carbamoyltransferase deficiency 187–193
- Urine
 electrolytes, adrenalectomy 577–583
 protein, Haemaccel 245–249
- Vagus, heart rate 335–341
- Vascular resistance
 converting enzyme inhibitor 657–667
 experimental papillary necrosis 599–604
 pulmonary, hypoxia 717–724
 skin blood vessels 123–130
 verapamil 657–667

- Vasoactive intestinal peptide, renal natriuresis
195–200
- Vasoconstriction, pulmonary, hypoxia 283–287
- Vasopressin
atrial natriuretic peptide 525–530
chronic renal failure, saline infusion 19–24
haemodynamic effects 147
sodium intake 25–30
- Ventilation, arterial oxygen saturation 693–698
- Vinyl chloride, skin collagen 673–678
- Water balance
exercise 611–619
high K⁺ diet, hypertension 321–327
- Zinc, experimental hypertension 515–518